Luminex Corporation was incorporated in May 1995 and began commercial production of the first generation system in 1997. Luminex® (NASDAQ: LMNX) develops, manufactures and markets innovative biological testing technologies with applications throughout the life science and diagnostic industries. The Company’s open-architecture xMAP® Technology enables large numbers of biological tests (bioassays) to be conducted and analyzed quickly, cost-effectively and accurately. Systems using xMAP Technology perform discrete bioassays on the surface of color-coded beads known as microspheres, which are then read in a compact analyzer. Using lasers and high-speed digital-signal processors, the analyzer simultaneously identifies the bioassay and measures the results, all in real time.
Luminex Vision Statement: Breakthrough solutions to improve health and advance science.

Type
Public
HQ
Austin, US
Size (employees)
914 (est)+15%
Luminex is headquartered in Austin, US

Luminex Office Locations

Luminex has offices in Austin, Madison, 's-Hertogenbosch, Toronto and in 2 other locations
Austin, US (HQ)
12212 Technology Blvd
Shanghai, CN
Room 353 No.3058 Pusan Road
Minato-ku, JP
Kamiyacho Sankei Bldg 3F 1-7-2 Azabudai
Toronto, CA
900 439 University Ave
's-Hertogenbosch, NL
1 Het Zuiderkruis
Madison, US
1224 Deming Way

Luminex Metrics

Luminex Financial Metrics

Revenue (2016)

$270.6 m

Revenue growth (2015-16), %

14%

Gross profit

$179.7 m

Gross profit margin (2016), %

66%

Net income (2016)

$13.8 m

Market capitalization (21-Mar-2017)

$737.5 m

Closing share price (21-Mar-2017)

$18.1

Cash (31-Dec-2016)

$93.5 m
Luminex's current market capitalization is $737.5 m.
Luminex's revenue was reported to be $270.6 m in FY, 2016 which is a 13.9% increase from the previous period.
FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

$10.7 m$227 m$237.7 m$270.6 m

Revenue growth, %

2021%5%14%

Cost of goods sold

$69.8 m$67.1 m$69 m$91 m

Gross profit

($59.1 m)$159.9 m$168.7 m$179.7 m

Gross profit Margin, %

(552%)70%71%66%

Operating expense total

$138.9 m$131.7 m$131.4 m$158.7 m

EBIT

$4.8 m$28.1 m$37.4 m$21 m

EBIT margin, %

45%12%16%8%

Pre tax profit

$11.4 m$28.1 m$33 m$19.6 m

Income tax expense

$6.1 m$9.5 m$10.4 m($4.3 m)$11 m$3.8 m($5.8 m)

Net Income

$7.1 m$39 m$36.9 m$13.8 m
Y, 2009Y, 2010Y, 2011Y, 2012Y, 2013Y, 2014Y, 2015FY, 2016

Cash

$90.8 m$89.5 m$58.3 m$42.8 m$67.9 m$91.7 m$128.5 m$93.5 m

Accounts Receivable

$30.9 m$29.1 m$28.9 m$32.4 m

Inventories

Current Assets

$146.4 m$177 m$209.5 m$173.7 m

PP&E

$32.8 m$39.9 m$47.8 m$57.4 m

Goodwill

$50.7 m$49.6 m$49.6 m$85.5 m

Total Assets

$306 m$357.5 m$402.6 m$450.7 m

Accounts Payable

$10.7 m$11.8 m$7.9 m$12.3 m

Total Debt

$1.7 m$1.7 m

Current Liabilities

$28.5 m$30.4 m$27.2 m$40.2 m

Additional Paid-in Capital

$296.9 m$309.4 m$321.7 m$336.4 m

Retained Earnings

($27.8 m)$11.3 m$48.1 m$68.9 m

Total Equity

$269.6 m$320 m$368.5 m$403.7 m

Debt to Equity Ratio

0 x

Debt to Assets Ratio

0 x

Financial Leverage

1.1 x1.1 x1.1 x1.1 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

$7.1 m$39 m$36.9 m$13.8 m

Depreciation and Amortization

$15.9 m$14.2 m

Accounts Receivable

$2.3 m$2 m

Inventories

Accounts Payable

$962 k$841 k

Cash From Operating Activities

$26.9 m$49.3 m$36.9 m

Purchases of PP&E

($18.1 m)($17.1 m)

Cash From Investing Activities

$2.7 m($28.5 m)

Luminex Market Value History

Luminex Median Salaries

Source: 16 public H-1B filings from Luminex

Luminex Online Presence

Luminex Company Life

You may also be interested in